Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Aviance Capital Partners LLC

Aviance Capital Partners LLC boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% in the 3rd quarter, Holdings Channel reports. The fund owned 18,616 shares of the biopharmaceutical company’s stock after purchasing an additional 1,138 shares during the period. Aviance Capital Partners LLC’s holdings in Gilead Sciences were worth $1,561,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. OneAscent Wealth Management LLC purchased a new stake in Gilead Sciences during the third quarter worth approximately $203,000. Quest Partners LLC grew its stake in shares of Gilead Sciences by 163.4% in the third quarter. Quest Partners LLC now owns 8,400 shares of the biopharmaceutical company’s stock valued at $704,000 after buying an additional 5,211 shares in the last quarter. AMG National Trust Bank raised its holdings in shares of Gilead Sciences by 7.4% during the 3rd quarter. AMG National Trust Bank now owns 66,993 shares of the biopharmaceutical company’s stock valued at $5,617,000 after buying an additional 4,638 shares during the period. Aljian Capital Management LLC acquired a new position in Gilead Sciences during the 3rd quarter worth approximately $479,000. Finally, TrinityPoint Wealth LLC boosted its holdings in Gilead Sciences by 658.5% in the 3rd quarter. TrinityPoint Wealth LLC now owns 43,606 shares of the biopharmaceutical company’s stock worth $3,656,000 after acquiring an additional 37,857 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.1 %

Shares of GILD stock opened at $88.46 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The stock’s 50 day simple moving average is $86.87 and its 200 day simple moving average is $76.27. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $110.25 billion, a price-to-earnings ratio of 982.89, a PEG ratio of 2.74 and a beta of 0.17.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same period last year, the business posted $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. As a group, research analysts predict that Gilead Sciences, Inc. will post 4.38 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.48%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock worth $4,968,674 over the last quarter. Company insiders own 0.29% of the company’s stock.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a research note on Friday, August 9th. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Royal Bank of Canada upped their price target on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research note on Monday. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target on the stock. Finally, Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $94.00.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.